Skip to main content

IceCure Medical Ltd.

corporate_fare Company Profile

IceCure Medical Ltd.

ICCM·NASDAQ·Industrial Applications And Services·CIK 0001584371

We are a commercial-stage medical device company that researches and develops cryoablation systems and disposable products using liquid nitrogen (LN2) to treat tumors. Cryoablation is a process that destroys benign and malignant tumors, nerves, or other tissues by freezing them inside a patient's body. Our cryoablation technology offers a minimally invasive alternative to surgery for tumors in areas like the breast, lungs, kidneys, bones, and other tissues. It is also used for nerve ablation to manage pain and treat conditions such as endometriosis. Our main commercial cryoablation product is the ProSense system and its associated CryoProbes. The FDA has authorized the ProSense system for marketing for the local treatment of low-risk breast cancer, when combined with adjuvant endocrine therapy, in women aged 70 and above, including those unsuitable for surgical alternatives. We are also developing new products, including the XSense system with CryoProbes, which has received 510(k) regulatory clearance from the FDA. We believe the XSense system can serve as a platform for developing other unique CryoProbes and catheters, expanding our clinical applications. Our product pipeline also includes MSense, which could enable the treatment of multiple and larger tumors.

IceCure Medical Ltd. (NASDAQ:ICCM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 48 items for ICCM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ICCM spans 6-K, F-3.

Recent high-impact activity:

  • Q3 Loss Narrower Than Expected at $0.40/Share, But Revenue Slips 3.1%
  • IceCure 9M 2026: Revenue Up 26% to $2.6M, U.S. Sales +83%, Cash Down to $8.2M
  • IceCure Seeks Authority for Up to 40-for-1 Reverse Split to Hold Nasdaq Listing
  • AMA Rejects Permanent CPT Code for IceCure's Breast Cryoablation — Reimbursement Stays Temporary
  • IceCure Wins China Approval for ProSense Cryoablation System

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.38M
Net Income
-$15.06M
Diluted EPS
$0.24
Op. Cash Flow
-$14.57M
Free Cash Flow
-$14.61M
Gross Profit
$1.23M
Operating Income
-$15.09M
Cash & Equivalents
$8.9M
Total Debt
$13K
Debt / Equity
0.00×
Net Margin
-445.6%
Shares Outstanding
73.12M sh
Source: 20-F · filed 2026-03-17 · accession 0001213900-26-028684

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 56,133 shares in ICCM as of the October 30, 2026 settlement, a 33.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 36.1% of ICCM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)56,133 shares as of October 30, 2026
Change vs prior period▲ 33.1%
Days to cover1.00 at avg daily volume of 91,935
Daily short volume (FINRA facilities)36.1% of 119,642 shares on November 20, 2026
5-day average short volume50.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ICCM, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

1 shelf registrationreverse split

Warrant Exercise Price Reduction · Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

ICCM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with I →
$0.9203 -7.70% today
52-week range · as of 2026-11-18 $0.65 – $22.5
Market cap
$4.45M
Volume
202.7K (0.9× avg)
3-mo avg 215.9K
Live data · 2026-11-21 13:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ICCM - Latest Insights

ICCM
Nov 18, 2026, 10:17 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.9946
Real-time Price: $0.9203 info
Change: -$0.0743 (-7%) info
Market Cap: $4.454M info
ICCM
Nov 18, 2026, 8:45 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.930
Real-time Price: $0.9203 info
Change: -$0.0097 (-1%) info
Market Cap: $4.454M info
ICCM
Nov 02, 2026, 4:50 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.8428
Real-time Price: $0.9203 info
Change: +$0.0775 (+9%) info
Market Cap: $4.454M info
ICCM
Oct 05, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.9203 info
Change: -$0.6797 (-42%) info
Market Cap: $4.454M info
ICCM
Sep 10, 2026, 8:59 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $0.9203 info
Change: -$1.16 (-56%) info
Market Cap: $4.454M info
ICCM
Sep 10, 2026, 8:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $0.9203 info
Change: -$1.20 (-57%) info
Market Cap: $4.454M info
ICCM
Aug 24, 2026, 7:50 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.48
Real-time Price: $0.9203 info
Change: -$1.56 (-63%) info
Market Cap: $4.454M info
ICCM
Aug 12, 2026, 8:45 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.20
Real-time Price: $0.9203 info
Change: -$2.28 (-71%) info
Market Cap: $4.454M info
ICCM
Aug 12, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $3.70
Real-time Price: $0.9203 info
Change: -$2.78 (-75%) info
Market Cap: $4.454M info
ICCM
Jul 06, 2026, 8:11 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $5.68
Real-time Price: $0.9203 info
Change: -$4.76 (-84%) info
Market Cap: $4.454M info
ICCM
Jul 02, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $5.36
Real-time Price: $0.9203 info
Change: -$4.44 (-83%) info
Market Cap: $4.454M info
ICCM
Jun 26, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.76
Real-time Price: $0.9203 info
Change: -$4.84 (-84%) info
Market Cap: $4.454M info
ICCM
Jun 25, 2026, 4:30 PM EDT
Filing Type: F-3
Importance Score:
9
Price at Filing: $7.00
Real-time Price: $0.9203 info
Change: -$6.08 (-87%) info
Market Cap: $4.454M info
ICCM
Jun 25, 2026, 8:45 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.25
Real-time Price: $0.9203 info
Change: -$7.33 (-89%) info
Market Cap: $4.454M info
ICCM
Jun 25, 2026, 8:12 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $8.62
Real-time Price: $0.9203 info
Change: -$7.70 (-89%) info
Market Cap: $4.454M info
ICCM
Jun 23, 2026, 8:10 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $6.12
Real-time Price: $0.9203 info
Change: -$5.20 (-85%) info
Market Cap: $4.454M info
ICCM
Jun 18, 2026, 4:47 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.49
Real-time Price: $0.9203 info
Change: -$4.57 (-83%) info
Market Cap: $4.454M info
ICCM
Jun 17, 2026, 1:14 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $9.17
Real-time Price: $0.9203 info
Change: -$8.25 (-90%) info
Market Cap: $4.454M info
ICCM
Jun 17, 2026, 8:25 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $2.14
Real-time Price: $0.9203 info
Change: -$1.22 (-57%) info
Market Cap: $4.454M info
ICCM
Jun 02, 2026, 8:45 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.1596
Real-time Price: $0.9203 info
Change: Reverse Stock Split info
Market Cap: $4.454M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets